Código QR

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

Abstract Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade (ICB)-based therapies mainly relies on PD-1/PD-L1 and CTLA-4 blockade. However, th...

Descrición completa

Gardado en:
Principais autores: Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Rocío Granda-Díaz, Alejandra Martínez-Pérez, Candelaria Aguilar-García, Juan P. Rodrigo, Juana M. García-Pedrero, Segundo Gonzalez
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2023-08-01
Series:Molecular Cancer
Assuntos:
Immunotherapy
BTLA
HVEM
Checkpoint blockade
T cell
NK cell
Acceso en liña:https://doi.org/10.1186/s12943-023-01845-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares